Compare NUVL & EMBJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | EMBJ |
|---|---|---|
| Founded | 2017 | 1969 |
| Country | United States | Brazil |
| Employees | N/A | 20744 |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.9B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | EMBJ |
|---|---|---|
| Price | $105.11 | $63.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $134.75 | $84.00 |
| AVG Volume (30 Days) | 616.4K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,239.49 | $13.60 |
| P/E Ratio | ★ N/A | $159.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.56 | $54.28 |
| 52 Week High | $113.02 | $80.75 |
| Indicator | NUVL | EMBJ |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 45.76 |
| Support Level | $100.98 | $60.76 |
| Resistance Level | $107.08 | $65.81 |
| Average True Range (ATR) | 3.38 | 2.13 |
| MACD | 0.12 | -0.38 |
| Stochastic Oscillator | 67.47 | 8.68 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.